Common Pharma

Common Pharma, Inc., is a pharmaceutical company developing medicine for hard-to-treat diseases. Our primary focus is development of a novel class of compounds with demonstrated preliminical effiectiveness in treatment of xenograft tumors and blocking IL-6 overexpression. Our patented molecules have also shown strong anti-bacterial efficacy, specifically aganist P. Acne and MRSA. The company has also an advanced, topical program to treat various dermal conditions and has shown clinical efficacy against vehicle to reduce facial blemishes.
About us

Our Programs

We are driven to help those suffering from chronic diseases and cancer
Common Pharma has discovered a new compound with significant, in vivo tumor growth reduction in multiple laboratory studies
Oncology
We are targeting colorectal cancer with plans to rapidly start a clinical trial to evaluate SLML against cancer.
Dermatology
Common Pharma has two major program and product for skin care. A new medicinal, patented compound and a patented, in-human tested, composition with proven efficacy in skincare.
About Common Pharma

Cutting Edge Biotech

Common Pharma, Inc. has multiple, patented technologies with application in several areas of medicine, oncology, dermatology, and immunology with proven efficacy and safety.
About Us
We strongly believe:

Cancer can be defeated

Sub Title

Research into Relationship between inflammation and chronic diseases will open many new therapeutic approaches

Text

Potential indications, Oncology:

Colorectal Cancer
Molecular expression and signaling is one of the most complicated biological process in living cells
Finding relationshionship between biolological process and chemical entities
Discovery of new chemicals
The solution to high cost of pharmaceuticals is in better udnerstanding diseases and development of safer drugs
Streamlining drug development
Similarity in diseases